List of Excipients in Branded Drug FENTORA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cephalon LLC	FENTORA	fentanyl	63459-541	ANHYDROUS CITRIC ACID
Cephalon LLC	FENTORA	fentanyl	63459-541	MAGNESIUM STEARATE
Cephalon LLC	FENTORA	fentanyl	63459-541	MANNITOL
Cephalon LLC	FENTORA	fentanyl	63459-541	SODIUM BICARBONATE
Cephalon LLC	FENTORA	fentanyl	63459-541	SODIUM CARBONATE
Cephalon LLC	FENTORA	fentanyl	63459-541	SODIUM STARCH GLYCOLATE TYPE A POTATO

Fentora Excipient Strategy and Commercial Opportunities in Buccal Fentanyl

Last updated: September 9, 2026

Fentora is an immediate-release fentanyl citrate buccal tablet for breakthrough cancer pain in opioid-tolerant adults. Its commercial differentiation comes from the OraVescent effervescent delivery platform, which uses gas-generating and pH-modifying excipients to improve fentanyl transport across the buccal mucosa. The strongest commercial opportunities are in generic or alternative buccal delivery systems, excipient supply, abuse-deterrent reformulation, and manufacturing technology rather than in undifferentiated excipient substitution.

What is Fentora and how does its buccal delivery system work?

Fentora contains fentanyl citrate in strengths of 100, 200, 400, 600, and 800 micrograms. The tablet is placed against the buccal mucosa, where it dissolves and delivers fentanyl through the cheek. It is indicated only for opioid-tolerant patients with breakthrough cancer pain and is subject to opioid-related safety controls.[1]

Fentora uses Cephalon’s OraVescent technology, later associated with Teva following Teva’s acquisition of Cephalon. The platform is designed to increase local pH and generate effervescence at the administration site. These effects can promote drug dissolution and transiently increase mucosal permeability.

The formulation strategy has four functional objectives:

1. Rapid tablet disintegration at the buccal site.
2. High fentanyl release from a small tablet.
3. Increased transmucosal absorption.
4. Reduced dependence on gastrointestinal absorption and first-pass metabolism.

The product therefore depends on formulation architecture, not only on the active pharmaceutical ingredient.

What excipients are used in Fentora?

Fentora’s inactive ingredients include mannitol, sodium bicarbonate, sodium carbonate, magnesium stearate, and citric acid, according to FDA product information.[1] The excipient system is commercially important because each component supports a distinct manufacturing or drug-delivery function.

Excipient or excipient class	Likely formulation function	Commercial relevance
Mannitol	Diluent, bulking agent, mouthfeel modifier, rapid-dissolution carrier	Supports low tablet mass and acceptable oral sensation
Sodium bicarbonate	Effervescent base and alkalizing agent	Generates carbon dioxide and raises local pH
Sodium carbonate	Alkalizing agent and effervescence component	Helps control microenvironmental pH and dissolution
Citric acid	Acid component for effervescence and pH control	Balances carbonate and bicarbonate chemistry
Magnesium stearate	Lubricant	Supports tableting and ejection from tooling

The combination of citric acid with carbonate and bicarbonate creates an effervescent reaction in the presence of saliva. The resulting carbon dioxide can disrupt the local boundary layer, while the alkaline microenvironment can increase the fraction of fentanyl present in a more membrane-permeable form.

Exact performance depends on particle size, moisture level, blend uniformity, compression force, tablet porosity, and the stoichiometric balance between acidic and basic components. A formulation with the same named excipients may not reproduce Fentora’s pharmacokinetic profile.

What excipient strategy protects Fentora’s performance?

Effervescent pH modulation

The principal strategy is local pH modulation. Fentanyl is a weak base, and the balance between ionized and unionized drug influences mucosal permeation. Carbonate and bicarbonate excipients can raise the local pH as the tablet hydrates.

The pH effect must be controlled. Excess alkalinity can affect tolerability, chemical stability, taste, and mucosal irritation. Insufficient alkalinity may reduce the intended absorption advantage.

Rapid hydration and dissolution

Mannitol is suitable for oral solid dosage forms because it has a relatively clean taste profile and can support rapid dissolution. Its use also reduces the amount of dense, poorly soluble filler that would otherwise remain in the buccal cavity.

The tablet must dissolve quickly without becoming friable during packaging, transport, or handling. This creates a narrow manufacturing window between mechanical robustness and rapid in-mouth disintegration.

Controlled lubrication

Magnesium stearate improves manufacturability but can slow wetting and dissolution if overused or excessively blended. Fentora-type products require tight control of lubricant concentration and blending time. Lubrication is therefore a process variable, not a routine excipient decision.

Taste and mouthfeel

Fentanyl products are administered to seriously ill patients, but taste remains commercially relevant. Salty or alkaline notes from carbonate salts can reduce acceptability. Mannitol, particle-size selection, and tablet geometry can moderate the sensory profile without adding a complex coating that slows dissolution.

What formulations are protected by Fentora’s intellectual property?

Fentora-related intellectual property historically covered more than a list of ingredients. Relevant claim categories have included:

• Effervescent transmucosal tablets.
• Buccal delivery of fentanyl or fentanyl analogues.
• pH-modifying excipient systems.
• Tablet compositions that enhance transmucosal absorption.
• Dosing methods for breakthrough cancer pain.
• Manufacturing and compression parameters.
• Product-specific strength and administration configurations.

The commercial value of the estate has depended on the interaction of composition, delivery method, and manufacturing claims. A generic developer may avoid a composition claim by changing the acid-base ratio, replacing one excipient, or using a different dosage form. That change still requires demonstration of acceptable bioavailability, safety, stability, and clinical performance.

Patent expiry does not remove regulatory barriers. Fentanyl remains a controlled substance, and buccal delivery creates product-specific bioequivalence issues.

What is the FDA regulatory status of Fentora?

Fentora was approved by the FDA under NDA 021947 as a prescription buccal tablet.[1] The product is approved for opioid-tolerant adults with breakthrough cancer pain, not for opioid-naive patients or routine treatment of non-cancer pain.

Key regulatory controls include:

• Controlled-substance requirements for fentanyl.
• Risk Evaluation and Mitigation Strategy obligations for transmucosal immediate-release fentanyl products.
• Restricted prescribing and dispensing controls.
• Strong warnings concerning respiratory depression, accidental exposure, misuse, abuse, addiction, and fatal overdose.
• Product-specific titration requirements.

The FDA’s opioid REMS framework increases operational costs for manufacturers, distributors, prescribers, and pharmacies.[2] A commercial entrant must establish controlled-substance security, diversion controls, pharmacovigilance, compliant labeling, and distribution procedures.

When does Fentora lose exclusivity?

Fentora’s practical exclusivity is determined by several layers:

Exclusivity layer	Relevance to Fentora
New drug exclusivity	Historically associated with the original NDA approval
Pediatric exclusivity	May extend relevant FDA-listed protections if granted
Orange Book patents	Composition, delivery, formulation, method-of-use, or manufacturing claims
Regulatory controls	REMS and controlled-substance requirements continue after patent expiry
Manufacturing know-how	Process control may remain commercially valuable even after patents expire
Market access	Prescriber familiarity, supply reliability, and payer positioning affect launch timing

The FDA Orange Book is the controlling source for currently listed patents and regulatory exclusivity information.[3] Patent expiration dates must be assessed patent by patent because terminal disclaimers, patent-term adjustment, pediatric extensions, and delisting can change the effective barrier.

A generic applicant may file an ANDA with a Paragraph IV certification if it believes an Orange Book-listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and, under the Hatch-Waxman framework, a potential 30-month stay of approval, subject to statutory conditions.[4]

How many patents cover Fentora?

The relevant number changes over time and depends on whether the analysis includes expired patents, Orange Book-listed patents, continuations, method-of-use patents, and patents covering the underlying OraVescent platform.

A reliable diligence review should separate:

1. Patents listed for the Fentora NDA.
2. Broader platform patents assigned to Cephalon or related entities.
3. Patents covering alternative buccal or sublingual fentanyl systems.
4. Litigation patents asserted against ANDA applicants.
5. Expired patents that still disclose formulation design but no longer block entry.

The distinction matters commercially. A broad formulation patent may constrain a directly substitutable product, while a narrow method-of-use patent may have limited value if the generic label uses a permitted carve-out.

Which companies are challenging or competing with Fentora?

Competition exists across several delivery technologies rather than only among identical tablets.

Product or technology	Dosage form	Delivery route	Competitive issue
Fentora	Buccal tablet	Buccal mucosa	Rapid transmucosal delivery with effervescent platform
Actiq	Oral transmucosal lozenge	Buccal/oral mucosa	Established fentanyl delivery but different administration profile
Onsolis	Buccal film	Buccal mucosa	Film-based delivery and different handling characteristics
Subsys	Sublingual spray	Sublingual mucosa	Liquid spray with rapid administration
Generic fentanyl buccal products	Buccal tablet	Buccal mucosa	Must address bioequivalence, controlled substance, and IP barriers

The most direct competitive threat comes from generic buccal tablets. Alternative products can compete on titration, administration time, ease of use, portability, adherence, and abuse-deterrence characteristics.

What commercial opportunities exist for Fentora excipients?

Supplying high-functionality excipients

Excipient suppliers can target pharmaceutical-grade mannitol, carbonate systems, citric acid, and tableting lubricants with tighter specifications for:

• Particle-size distribution.
• Water content.
• Microbial limits.
• Bulk density.
• Flowability.
• Compaction behavior.
• Trace metal control.
• Lot-to-lot pH performance.

The commercial opportunity is stronger where the supplier provides a qualified grade, process support, and regulatory documentation rather than a commodity material.

Developing replacement excipients

Potential alternatives include:

• Direct-compression mannitol grades.
• Co-processed mannitol-based excipients.
• Alternative carbonate or bicarbonate sources.
• Low-moisture acidulants.
• Lubricants with reduced dissolution impact.
• Taste-masked alkaline components.
• Mucoadhesive polymers used at low levels.

Replacement excipients must preserve critical quality attributes, including disintegration, dissolution, buccal residence time, local pH, assay uniformity, impurity profile, and pharmacokinetics.

Building abuse-deterrent platforms

An abuse-deterrent buccal formulation could create a differentiated product, but the technical challenge is substantial. The formulation must resist crushing, extraction, dose dumping, or manipulation without undermining rapid buccal delivery. FDA abuse-deterrence guidance requires comparative laboratory and, where applicable, clinical evidence.[5]

Licensing delivery technology

Companies with patents or know-how in effervescent transmucosal delivery may license:

• Acid-base effervescence systems.
• Rapid-release buccal tablets.
• Mucoadhesive matrices.
• Low-dose potent-drug content uniformity processes.
• Specialized blister packaging.
• Controlled-substance manufacturing systems.

Licensing value is highest where the technology delivers a measurable pharmacokinetic or manufacturing advantage and is supported by freedom-to-operate analysis.

What manufacturing and IP barriers affect generic Fentora entry?

The principal manufacturing barriers are content uniformity, low-dose handling, compression control, moisture management, and packaging integrity.

Fentanyl is highly potent. Small deviations in blend uniformity or tablet weight can have a disproportionate clinical effect. Manufacturing must control:

• Segregation during blending and transfer.
• Static charge and powder adhesion.
• Cleaning validation.
• Operator exposure.
• Cross-contamination.
• Tablet weight and hardness.
• Moisture-driven effervescence before administration.
• Dose uniformity across strengths.

Packaging is also part of the product strategy. Unit-dose, child-resistant, tamper-evident systems can reduce accidental exposure and diversion risk. The package must protect the tablet from humidity while allowing compliant dispensing.

What generic launch scenarios exist?

Direct generic tablet

A direct generic buccal tablet has the largest addressable substitution opportunity but faces the highest bioequivalence and IP burden. The applicant must match the reference product’s critical performance attributes without necessarily copying every excipient.

Reformulated buccal tablet

A reformulated tablet may use a different excipient system or compression process. It can avoid selected patent claims but may require a more complex demonstration of equivalence.

Buccal film or sublingual product

A film or spray can compete clinically without being substitutable through an ANDA. The product would generally require a separate regulatory pathway and may support premium pricing through administration or adherence benefits.

Hospital or specialty-channel product

A product designed for oncology specialty pharmacies and controlled distribution can compete through supply reliability and support services. The market remains constrained by indication, REMS obligations, and opioid prescribing controls.

How strong is the Fentora patent estate?

The estate is strongest where claims combine:

• Fentanyl or fentanyl citrate.
• Buccal or transmucosal administration.
• Effervescent pH modification.
• Defined release or absorption performance.
• Specific dosage strengths.
• Manufacturing parameters that are difficult to design around.

Its strength is weaker where claims cover broad excipient classes or generic effervescent concepts that can be implemented through multiple formulations. Expired platform patents may retain technical relevance but do not independently block commercial entry.

The practical barrier is therefore a combination of patent scope, formulation know-how, controlled-substance regulation, and the cost of demonstrating reliable low-dose transmucosal performance.

What is the revenue exposure and market outlook?

Fentora’s revenue exposure depends on the size of the breakthrough cancer pain market, the availability of generic alternatives, reimbursement, and the status of the branded product in each jurisdiction. The product is a specialty opioid with a narrower patient population than oral immediate-release analgesics.

Commercial value is concentrated in:

• High-strength presentations.
• Reliable specialty distribution.
• Generic substitution economics.
• Formulation know-how that reduces development time.
• Excipient platforms that can be reused across other transmucosal drugs.

The broader opportunity may be larger in platform applications than in Fentora itself. The same formulation principles can apply to other potent, rapidly acting drugs where buccal delivery improves onset or reduces gastrointestinal variability.

Key Takeaways

• Fentora is a fentanyl citrate buccal tablet based on an effervescent OraVescent delivery strategy.
• Mannitol, sodium bicarbonate, sodium carbonate, citric acid, and magnesium stearate support distinct formulation and manufacturing functions.
• The central technical value is local pH modulation and rapid transmucosal release, not the individual excipients alone.
• Generic entry requires control of low-dose content uniformity, moisture, compression, dissolution, pharmacokinetics, and controlled-substance manufacturing.
• The FDA Orange Book, patent-family analysis, and Paragraph IV litigation history determine the effective exclusivity position.
• Commercial opportunities are strongest in qualified excipient grades, alternative effervescent systems, abuse-deterrent delivery, packaging, and licensed transmucosal platforms.
• Direct substitution is more constrained than competition from buccal films, sublingual sprays, and other fentanyl delivery systems.

FAQs

Can a generic Fentora product use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product meets applicable quality, safety, labeling, and bioequivalence requirements. A change in the acid-base system can materially affect pH, dissolution, and fentanyl absorption.

Is mannitol essential to the Fentora formulation?

No. Mannitol is a functional choice for dilution, mouthfeel, and rapid dissolution. A different filler may be possible, but the replacement must preserve tablet performance and pharmacokinetic equivalence.

Does an effervescent formulation automatically provide abuse deterrence?

No. Effervescence can improve transmucosal delivery but does not, by itself, demonstrate resistance to crushing, extraction, injection, or dose dumping. Abuse-deterrent claims require separate evidence.

Are Fentora excipients patentable on their own?

Individual excipients are generally established materials. Patent value may arise from their specific combination, ratio, particle characteristics, process conditions, or use in a defined transmucosal delivery system.

Can Fentora technology be used for non-opioid drugs?

Potentially. Effervescent buccal delivery may be relevant to potent, rapidly acting non-opioid drugs, but each application requires independent assessment of dose, permeability, stability, local tolerability, and regulatory suitability.

References

1. U.S. Food and Drug Administration. (2023). Fentora (fentanyl citrate) buccal tablet prescribing information.
2. U.S. Food and Drug Administration. (2020). Opioid analgesic risk evaluation and mitigation strategy.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Content and format of abbreviated applications.
5. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling.